ELV vs OSCR

Key Takeaways

• Elevance Health is a diversified healthcare giant with roughly $198 billion in annual revenue and over 45 million members, while Oscar Health is a fast-growing, technology-driven insurer with approximately 2 million members and $11.7 billion in 2025 revenue.
• ELV offers stable cash flows, a quarterly dividend, and an aggressive share buyback program, whereas OSCR reinvests heavily in growth and has yet to demonstrate consistent profitability.
• OSCR has delivered dramatically higher share-price momentum — roughly 96% year-to-date — versus ELV's approximately 9% year-to-date gain, but OSCR also carries significantly higher volatility with a beta of 2.34 compared to ELV's 0.68.
• Both companies face medical cost pressures, but ELV's scale and diversification across commercial, Medicaid, Medicare Advantage, and Carelon services provide greater resilience than OSCR's largely individual-market concentration.
• OSCR's 2026 revenue guidance of $18.7–$19.0 billion represents a projected leap from $11.7 billion, signaling a transformational growth trajectory that contrasts sharply with ELV's expected low-single-digit revenue decline in 2026.

Introduction

Comparing ELV (Elevance Health) and OSCR (Oscar Health) offers a revealing look at two very different approaches to the health insurance market. One is a Blue Cross Blue Shield-affiliated industry titan with decades of operating history, tens of millions of members, and a diversified revenue base spanning public and private insurance segments. The other is a younger, tech-forward disruptor that has grown rapidly in the individual ACA (Affordable Care Act) market by emphasizing digital experience and AI-driven operations. This comparison is particularly relevant for investors weighing stability and income against growth potential and higher volatility, as both stocks have drawn considerable attention in recent months for markedly different reasons.

ELV Overview and Recent Performance

Elevance Health, formerly known as Anthem, is one of the largest health insurers in the United States, serving approximately 45.2 million members through its Health Benefits segment and operating the fast-growing Carelon health services platform. The company generated $197.6 billion in operating revenue for full-year 2025, a 13% increase over the prior year, driven by higher premium yields, recent acquisitions, and Medicare Advantage membership expansion. In recent weeks, shares of ELV have traded near the $377 level, reflecting a roughly 9% gain year-to-date and a one-year advance of approximately 37%. However, the stock has faced headwinds tied to a rising medical loss ratio (MLR — the percentage of premiums spent on medical claims), which reached 90.0% for full-year 2025, up 150 basis points from 2024. Management's 2026 guidance for adjusted diluted EPS (earnings per share) of at least $25.50, down from $30.29 in 2025, disappointed markets earlier this year, though the company continues to return significant capital to shareholders — $4.1 billion in 2025 via dividends and share repurchases — and has reaffirmed confidence in returning to at least 12% average annual adjusted EPS growth by 2027.

OSCR Overview and Recent Performance

Oscar Health is a technology-focused health insurer built around a proprietary full-stack platform, with a mission to simplify and humanize the healthcare experience. The company primarily serves the individual and small group markets through ACA exchanges, ending 2025 with a record 2.04 million members. Full-year 2025 revenue reached $11.7 billion, up 27.5% from $9.2 billion in 2024, though the company posted a net loss of $443.2 million for the year as elevated medical costs and risk-adjustment dynamics weighed on profitability. Recent market activity has been notably favorable for OSCR: the stock has surged roughly 96% year-to-date and nearly 99% over the past twelve months, recently trading around $28 per share. The dramatic price appreciation has been fueled by investor enthusiasm around the company's 2026 outlook, which projects total revenue between $18.7 billion and $19.0 billion, an MLR improving to 82.4%–83.4%, and operating earnings of $250 million to $450 million — a potential return to profitability at scale. In early 2026, Oscar also secured a $475 million revolving credit facility, strengthening its balance sheet for the growth push ahead.

Trending AI Robots

For traders seeking an analytical edge in evaluating stocks like ELV and OSCR, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots designed to navigate evolving market conditions. Tickeron maintains hundreds of AI trading bots that trade thousands of different tickers, each employing distinct trading styles, strategies, timeframes, and performance statistics. Only the bots that demonstrate the strongest alignment with current market dynamics earn a place in the Trending AI Robots section. This curated selection helps users quickly identify AI-driven trading tools with relevant track records, from short-term swing trading bots to longer-horizon trend-following models. For investors and traders interested in supplementing their own analysis with real-time algorithmic insights, exploring the Trending AI Robots page can be a practical next step.

Head-to-Head Comparison

The contrast between ELV and OSCR is largely a study in scale versus speed, and stability versus speculation. Elevance Health's diversified business model spans commercial employer plans, Medicaid, Medicare Advantage, and the high-growth Carelon services division — which generated a 35.8% revenue increase in a recent quarter. This diversification partially insulates ELV from weakness in any single line of business, though Medicaid margin pressure and ACA cost trends have weighed on recent results. In contrast, Oscar Health is heavily concentrated in the individual ACA market, which creates outsized exposure to regulatory shifts, including the potential expiration of enhanced premium subsidies. On the other hand, OSCR's technology-first approach and aggressive expansion into new counties and product categories — including condition-specific plans and the Oswell AI health assistant — position it as a potential market-share winner if the individual market continues to grow.

From a risk perspective, ELV's low beta of 0.68 and consistent dividend suggest defensive characteristics, while OSCR's beta of 2.34 reflects a high-volatility, growth-oriented profile. Valuation metrics also diverge sharply: ELV trades at roughly 15–16 times forward earnings with a price-to-sales ratio around 0.47, whereas OSCR's negative trailing earnings and price-to-sales ratio of roughly 0.58 reflect the market pricing in future profitability that has yet to materialize. Sentiment-wise, OSCR has benefited from powerful upward momentum, but that momentum is coupled with elevated short interest — roughly 6.5% of shares outstanding — indicating meaningful skepticism alongside the enthusiasm.

Tickeron AI Verdict

Based on observable factors such as trend consistency, stability, relative valuation, and catalyst visibility, Tickeron's AI-driven analytical framework would likely favor ELV for risk-conscious positioning at this juncture, while acknowledging that OSCR presents a more compelling momentum and growth narrative. ELV's combination of strong operating cash flow, a well-capitalized balance sheet, robust shareholder returns, and a diversified revenue base offers the kind of structural stability that quantitative models tend to reward in uncertain or mixed market environments. OSCR's dramatic price appreciation and ambitious 2026 targets suggest significant upside potential, but the company's concentrated exposure to the individual ACA market, lack of consistent profitability, and high beta introduce variables that reduce trend reliability in probabilistic AI assessments. Ultimately, the AI verdict reflects a preference for ELV's risk-adjusted profile, while recognizing OSCR as a high-energy contender that could outperform if its growth trajectory materializes as planned.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations